Active Pharmaceutical Ingredient (API)

  1. Location
  2. Home
  3. News
  4. Active Pharmaceutical Ingredient (API)

Premium API Supply - High-Purity Ruxolitinib (99%+) – Kilogram-Scale Available

2026-07-15 10:17:42
Executive Summary
We offer high-purity (≥99.0%) Ruxolitinib (CAS 941678-49-5) in kilogram (KG) to multi-kilogram scales for global export. As the first approved JAK1/JAK2 inhibitor globally, Ruxolitinib demands extraordinary asymmetric synthesis controls and polymorph management. Through our advanced catalytic platforms and precise crystallization technologies, we consistently control the critical (R)-enantiomer and maintain an exceptional impurity profile. We provide a complete technical documentation package (COA, HPLC, Chiral-HPLC, H-NMR, MS, MSDS) to fully support generic pharmaceutical developers, oncology research centers, and topical formulation labs worldwide.

continuous flow microchannel reactor

Product Specifications & Identification

  • Chemical Name: Ruxolitinib (Jakafi / Opzelura),INCB018424, (R)-Ruxolitinib

  • CAS Registry Number: [941678-49-5] 

  • Molecular Formula: C₁₇H₁₈N₆

  • Molecular Weight: 306.37

  • IUPAC Name: (3R)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]-3-cyclopentylpropanenitrile

  • Appearance: Off-white to white crystalline powder

  • Purity (HPLC): ≥ 99.0%

  • Chiral Purity (ee): ≥ 99.0% (Strictly controlled restriction enantiomer)

  • Single Impurity: ≤ 0.1%

  • Storage: Store in a cool, dry, well-ventilated area. Keep container tightly sealed at 2-8°C, away from strong light, heat, and moisture.

Key Advantages for Global Procurement
1. Rigorous Chiral & Stereochemical Control

  • High-Yield Asymmetric Synthesis: Ruxolitinib's efficacy relies heavily on its stereospecific (R)-chiral center. Our validated asymmetric hydrogenation process ensures a superior enantiomeric excess (ee value), keeping unwanted chiral impurities down to trace levels.

  • Polymorphic Consistency: Strict crystal form control guarantees batch-to-batch uniformity, ensuring reliable dissolution profiles and predictable bioavailability for oral solid dosage forms or topical emulsions.

2. Robust Kilogram-to-Ton Production Scales

  • Secured Upstream Chain: We have a fully backward-integrated production line with self-produced key intermediates, eliminating any risks of external material supply chain disruptions.

  • Immediate Delivery Stock: We maintain a continuous, stable inventory of kilogram-scale stock at our export warehouse, enabling 24-to-48-hour order dispatch for your urgent pilot-trial or clinical batch needs.

3. Full Analytical Packages & Regulatory Support

  • Multi-Dimensional Testing: Every single batch undergoes stringent identification and characterization via physical HPLC, Chiral-HPLC, Proton NMR (H-NMR), and Mass Spectrometry (MS).

  • Documentation Package: Shipments are accompanied by standard Certificate of Analysis (COA), Method of Analysis (MOA), and Material Safety Data Sheet (MSDS). Further documentation for generic drug dossier compilation is available upon corporate review.

Core Applications & R&D Pipelines
As a powerful JAK1 and JAK2 tyrosine kinase inhibitor, Ruxolitinib remains a high-demand compound across hematology and dermatology pipelines:

  • Hematology & Oncology Solids: Formulation development for generic oral medications targeting Myelofibrosis (MF) and Polycythemia Vera (PV).

  • Dermatological Topicals: Formulation and處方 development for topical creams and ointments targeting Non-segmental Vitiligo and mild-to-moderate Atopic Dermatitis (AD).

  • Immunological Research: Investigational pipelines exploring treatments for Graft-versus-Host Disease (GvHD).

Packaging, Logistics & Compliance

  • Secure Export Packaging: 100g/Aluminum foil bag; 1kg/Aluminum foil bag (lined with double-layer heavy-duty PE bags); 5kg/HDPE drum; 25kg/Fiber drum. Customized or split packaging is available upon request.

  • Compliant Logistics: Shipped via premier, licensed international chemical freight forwarders. We arrange all essential export licenses and customs documents to ensure smooth transit and rapid clearance at global destination ports.

  • Patent Disclaimer: In strict compliance with global intellectual property and patent laws, this product is strictly offered for laboratory research, formulation R&D, and generic drug filing purposes (e.g., under Bolar exemptions). No commercial supply will be delivered into countries where active compound patents are infringed. The buyer bears full responsibility for validating local patent constraints.


为您推荐